Lovastatin-Mevinolin-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemELovastatinCat.No.:HY-N0504CASNo.:75330-75-5Synonyms:Mevinolin分⼦式:C₂₄H₃₆O₅分⼦量:404.54作⽤靶点:HMG-CoAReductase(HMGCR);Autophagy;Ferroptosis作⽤通路:MetabolicEnzyme/Protease;Autophagy;Apoptosis储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:≥100mg/mL(247.19mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制备储备液1mM2.4719mL12.3597mL24.7194mL5mM0.4944mL2.4719mL4.9439mL10mM0.2472mL1.2360mL2.4719mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(6.18mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.18mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(6.18mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Lovastatin⼀种⽤于降低胆醇的细胞渗透性的HMG-CoA还原酶抑制剂。IC50&TargetHMG-CoAreductase[1]体外研究Lovastatin(10μM;72hours)efficientlyreducesviabilityofHepG2cells[2].Lovastatin(10μM;48hours)inducesapoptosisinHepG2cells[2].CellViabilityAssay[2]CellLine:HepG2cellsConcentration:10μMIncubationTime:72hoursResult:EfficientlyreducedviabilityofHepG2cells.体内研究Lovastatinisaninactivelactonethatishydrolyzedinthelivertoanactivef3-hydroxyacidform.ThisprincipalmetaboliteistheinhibitoroftheenzymeHMG-CoAreductase.TheKiis1nM.Lovastatinanditsβ-hydroxyacidmetabolitearehighlyboundtohumanplasmaproteins.Lovastatincrossestheblood-brainandplacentalbarriers[3].Lovastatinproducesaprofoundreductionofapolipoprotein-B-containinglipoproteins,especiallyLDLcholesteroland,toalesserextent,plasmatriglycerides,andasmallincreaseinHDLcholesterol[4].户使⽤本产品发表的科研⽂献•CellMetab.2020Apr7;31(4):741-754.e5.•RedoxBiol.2022Feb;49:102207.•CellDeathDis.2019Apr11;10(4):327.•JCIInsight.2022Aug9;e161940.•FrontBioengBiotechnol.2022Mar17;10:826093.Seemorecustomervalidationsonwww.MedChemEREFERENCES2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE[1].AlbertsAW,etal.Discovery,biochemistryandbiologyoflovastatin.AmJCardiol.1988Nov11;62(15):10J-15J.[2].KahJ,etal.SelectiveinductionofapoptosisbyHMG-CoAreductaseinhibitorsinhepatomacellsanddependenceonp53expression.OncolRep.2012Sep;28(3):1077-83.[3].FrishmanWH,etal.Lovastatin:anHMG-CoAreductaseinhibitorforloweringcholesterol.MedClinNorthAm.1989Mar;73(2):437-48.[4].TobertJA,etal.Lovastatinandbeyond:thehistoryoftheHMG-CoAreductaseinhibitors.NatRevDrugDiscov.2003Jul;2(7):517-26.[5].IferganI,etal.Statinsreducehumanblood-brainbarrierpermeabilityandrestrictleukocytemigration:relevancetomultiplesclerosis.AnnNeurol.2006Jul;60(1):45-55.McePdfHeightCaution:Producthasnotbeenfull